Insider Transactions in Q4 2025 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,381
+1.66%
|
$173,813
$73.95 P/Share
|
|
Dec 12
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,804
-6.45%
|
$339,152
$188.31 P/Share
|
|
Dec 08
2025
|
Jason Aryeh Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,034
+2.77%
|
$140,346
$69.51 P/Share
|
|
Dec 05
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,862
-6.24%
|
$342,608
$184.87 P/Share
|
|
Dec 04
2025
|
Todd C Davis Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
130
-0.08%
|
-
|
|
Dec 01
2025
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
467
-0.15%
|
$91,532
$196.82 P/Share
|
|
Nov 07
2025
|
Nancy Ryan Gray Director |
SELL
Open market or private sale
|
Direct |
6,571
-28.83%
|
$1,347,055
$205.45 P/Share
|
|
Nov 07
2025
|
Nancy Ryan Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,571
+22.37%
|
$453,399
$69.88 P/Share
|
|
Nov 07
2025
|
John L Lamattina Director |
SELL
Open market or private sale
|
Direct |
4,179
-6.37%
|
$856,695
$205.45 P/Share
|
|
Nov 07
2025
|
John L Lamattina Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,179
+5.99%
|
$279,993
$67.82 P/Share
|
|
Nov 03
2025
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
467
-0.26%
|
$88,730
$190.72 P/Share
|
|
Oct 01
2025
|
John W Kozarich Director |
SELL
Open market or private sale
|
Direct |
467
-0.26%
|
$83,593
$179.3 P/Share
|